ProPhase Labs (PRPH)
Operator of whole-genome sequencing, esophageal diagnostics, and OTC supplement brands.
Something off on this page? Send us feedback.
ProPhase Labs combines consumer genomics, BE-Smart esophageal cancer diagnostics, biopharma assets, and OTC supplements. Recent company updates also center on recovering unpaid COVID-era laboratory testing claims, while its operating base depends on commercialization partners, collections, and regulated clinical testing workflows.
ProPhase Labs is a healthcare company organized around consumer products and diagnostic services, with current emphasis on Nebula Genomics and DNA Complete whole-genome sequencing, BE-Smart esophageal cancer risk testing, ProPhase BioPharma compounds, and TK Supplements. Its products are primarily developed, marketed, or serviced from the United States, while the consumer genomics offering is sold online and can serve customers outside the country through digital reports and subscriptions.
The company has shifted away from broad COVID testing operations and is pursuing recovery of unpaid or underpaid testing claims through Crown Medical Collections. Management has also started a sale or partnership process for BE-Smart to reach clinical distribution without carrying the full commercialization burden internally. The business depends on clinical validation, CLIA and laboratory-developed-test requirements, privacy handling for genetic data, partner distribution, and the timing of collections.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $20.0K · Total debt $9.1M · Total assets $57.4M · Shareholders' equity −$3.1M
- Revenue
- $1.0M
- Operating income
- −$2.6M
- Net income
- −$3.1M
HistoryDividendAnnual yield
| Institutions | 1.92% | 299.2K shares | |
|---|---|---|---|
| 31 holders · as of Sep 30, 2025 | |||
| Insiders | 3.42% | 533.3K shares | |
| 2 holders · as of Oct 18, 2022 | |||
| Other | 94.66% | 14.76M shares | |
| remainder | |||
15.59M company shares as of Sep 22, 2026 · institutions as of Sep 30, 2025 · holders as of their latest filing
Two share counts disagree (15.59M in the company's Sep 22, 2026 report, 14.02M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ted KarkusInsider | 2.74% | 427,132 | filed Oct 18, 2022 |
Mark LeventhalInsider | 0.68% | 106,198 | filed Jan 27, 2017 |
Sykon Capital LLCInstitution | 0.41% | 644,795 | as of Sep 30, 2025 |
Vanguard Group IncInstitution | 0.34% | 531,919 | as of Sep 30, 2025 |
Susquehanna International Group, LLPInstitution | 0.26% | 397,914 | as of Sep 30, 2025 |
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.